Mesabi Trust

Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar

Mesoblast hosted a key opinion leader webinar featuring pediatric transplant specialist Dr. Susan Prockop on use of Ryoncil first line after steroids in pediatric acute graft-versus-host disease. Dr. Prockop presented case studies and pivotal trial results supporting Ryoncil as a new treatment paradigm beyond its approved steroid-refractory pediatric aGvHD indication. Ryoncil remains the first FDA-approved mesenchymal stromal cell therapy; broader first-line adoption would expand its commercial opportunity, though this release contains no new clinical or financial data.

•4d ago

Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)

Mesoblast reported preliminary fiscal Q1 results with RYONCIL net revenue of $28 million, up 44% year-over-year, and September marking the highest month of new patient starts. Operating cash spend fell 86% to $2.1 million from $14.9 million a year earlier, leaving the company with $99 million in cash at quarter end. On the pipeline, all 350 patients in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain have completed treatment, with the 12-month durable pain reduction primary endpoint reading out next year. The FDA also confirmed the BLA filing for rexlemestrocel-L may proceed for prevention of life-threatening GI bleeding in LVAD heart-failure patients, under RMAT and Orphan Drug designations.

•11d ago